Compare Amylx Pharmaceuticals Inc (AMLX) vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $243.22 (market cap $45.15B). The key difference: TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is far larger — about 22.8× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock nearer its low. Which is the better fit depends on your goals.
| AMLX | TTWO | |
|---|---|---|
Market Cap | $1.98B | $45.15B |
Sector | Health | Media |
52-Week High | $18.70 | $262.29 |
52-Week Low | $7.64 | $189.69 |
Enterprise Value | $1.70B | $46.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Take-Two Interactive (TTWO) trades at $243.20, down 1.18% on the day, with a bullish technical outlook and strong analyst support. The stock shows consistent earnings beats, including Q1 2026 EPS of $0.80 versus $0.563 expected, and benefits from positive sentiment around Grand Theft Auto VI pre-orders. However, fundamentals reveal challenges with a net income margin of -4.48% and negative ROE of -10.56%, though revenue grew to $5.63B in 2025. Cash flow improved with net cash flow of $457.20M in 2025, driven by financing activities.
The outlook is optimistic due to GTA VI's upcoming launch, with a consensus price target of $302.50 implying 24% upside. Risks include high debt levels, with debt-to-asset ratio at 39.87% in 2025, and reliance on blockbuster game success. Institutional sentiment is strongly bullish, with 79% of analysts rating Buy, but investors should monitor execution on profitability targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →
